The international Structural Genomics Consortium is trying to find out how its basic research can better serve the priorities of UK drug development.
The consortium is a not-for-profit, public-private partnership with an “open access research programme”. It aims to publish details of human proteins—potential biological targets for drugs—for free, for anyone to use.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.